An integrative mechanistic model of thymocyte dynamics

• Published in: Frontiers in immunology Vol. 15; p. 1321309
• Main Authors: Kulesh, Victoria, Peskov, Kirill, Helmlinger, Gabriel, Bocharov, Gennady
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 26.02.2024
• Subjects: Animals; Cell Differentiation; Fingolimod Hydrochloride - metabolism; Fingolimod Hydrochloride - pharmacology; Fingolimod Hydrochloride - therapeutic use; Humans; immune system; Immunology; mechanistic model; Mice; Multiple Sclerosis - metabolism; thymic involution; Thymocytes - metabolism; thymopoiesis; thymus; Thymus Gland; immune system; thymus; thymic involution; mechanistic model; thymopoiesis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1321309

The thymus plays a central role in shaping human immune function. A mechanistic, quantitative description of immune cell dynamics and thymic output under homeostatic conditions and various patho-physiological scenarios are of particular interest in drug development applications, e.g., in the identification of potential therapeutic targets and selection of lead drug candidates against infectious diseases. We here developed an integrative mathematical model of thymocyte dynamics in human. It incorporates mechanistic features of thymocyte homeostasis as well as spatial constraints of the thymus and considerations of age-dependent involution. All model parameter estimates were obtained based on published physiological data of thymocyte dynamics and thymus properties in mouse and human. We performed model sensitivity analyses to reveal potential therapeutic targets through an identification of processes critically affecting thymic function; we further explored differences in thymic function across healthy subjects, multiple sclerosis patients, and patients on fingolimod treatment. We found thymic function to be most impacted by the egress, proliferation, differentiation and death rates of those thymocytes which are most differentiated. Model predictions also showed that the clinically observed decrease in relapse risk with age, in multiple sclerosis patients who would have discontinued fingolimod therapy, can be explained mechanistically by decreased thymic output with age. Moreover, we quantified the effects of fingolimod treatment duration on thymic output. In summary, the proposed model accurately describes, in mechanistic terms, thymic output as a function of age. It may be further used to perform predictive simulations of clinically relevant scenarios which combine specific patho-physiological conditions and pharmacological interventions of interest.